Mural Oncology Announces Sanction of the Scheme by the High Court

Core Viewpoint - Mural Oncology plc has received approval from the High Court of Ireland for a scheme of arrangement that will allow XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire all issued shares of Mural [1] Group 1: Acquisition Details - The scheme and acquisition will take effect upon the delivery of the Court Order to the Irish Registrar of Companies [2] - The effective date for the acquisition is expected to be December 5, 2025, with trading of Mural shares on Nasdaq ceasing on December 4, 2025 [3] - The cancellation of Mural shares from trading on the Nasdaq Global Market is anticipated to occur at 8:00 PM (U.S. Eastern Time) on December 4, 2025 [3] Group 2: Financial Considerations - Distribution of cash consideration to scheme shareholders is expected to begin shortly after the effective date, with completion anticipated by December 19, 2025 [4]